---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041156"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:47:19.561283+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AgeX Q3 net loss $5.4M; $36M debt converted to preferred; going concern raised

## Summary
- Net loss of $5.4M ($0.14 diluted EPS) vs $2.4M loss ($0.06) in Q3 2022.
- Cash and equivalents only $0.4M at Sept 30; received $4.4M credit line increase from Juvenescence.
- Converted $36M of debt into Series A/B preferred stock in July, eliminating that liability.
- Signed merger agreement to acquire Serina Therapeutics; G&A surged due to deal costs.
- Company discloses substantial doubt about ability to continue as going concern.

## SEC filing metadata
- accession: 0001493152-23-041156
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/0001493152-23-041156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041156
- JSON: https://secwatch.observer/filing/0001493152-23-041156.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041156.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported quarter and nine months ended September 30, 2023 results: net income $5.4 million, or ($0.14) per share (basic and diluted), EPS ($0.14) per share (basic and diluted).
  - Period: quarter and nine months ended September 30, 2023
  - Net income: $5.4 million, or ($0.14) per share (basic and diluted)
  - EPS: ($0.14) per share (basic and diluted)
  - Result: reported results
  source text: AgeX issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/0001493152-23-041156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.